SAN FRANCISCO, March 31, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman reminds investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) that the deadline to move for Lead Plaintiff in the pending securities class action is April 21, 2026. The firm urges Corcept investors who suffered significant losses to contact the firm now to discuss their rights. The lawsuit, Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., et al., No. 26-cv-01525, was filed ...

Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disordersCentessa’s OX2R agonist pipeline was jointly discovered by Nxera and Centessa, and Nxera retains a material economic interest in its future development and commercialization Tokyo, Japan and Cambridge, UK, 1 April 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that its partner, Centessa Pharmaceuticals Limited (“Centessa”), has announced that it entered into a def ...

New York, New York--(Newsfile Corp. - March 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks | Reuters Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Wegovy presentation is displayed in New Columbia, Pennsylvania, U.S., November 13, 2023. REUTERS/Hannah Beier/Illustration/File Photo Purchase Licensing Rights, opens new tab April 1 (Reuters) - UK's drug cost-effectiveness watchdog has recommended Novo Nordisk's (NOVOb.CO), opens new tabWegovy to reduce the risk of serious h ...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Soleno and certain ...

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Aldeyra and certai ...

Oric Pharmaceuticals (NasdaqGS:ORIC) Update / briefing March 31, 2026 04:30 PM ET Company ParticipantsAnupam Rama - VPDavid Nierengarten - Managing Director and Head of Healthcare Equity ResearchDominic Piscitelli - CFOErik Wong - Biotechnology Equity Research AssociateJacob Chacko - CEOKeith Lui - SVP of Commercial and Medical AffairsLori Friedman - Chief Scientific OfficerMatthew Biegler - Managing DirectorPrakhar Agrawal - Managing DirectorPratik Multani - Chief Medical OfficerSimone Nasroodin - Biotechn ...

BioHarvest Sciences (NasdaqGM:BHST) Q4 2025 Earnings call March 31, 2026 04:30 PM ET Company ParticipantsBar Dichter - CFOIlan Sobel - CEOJustin Meiklem - Head of Investor RelationsZaki Rakib - ChairmanConference Call ParticipantsAnthony Vendetti - Executive Managing Director and Director of Research and Senior Healthcare AnalystMatt Hewitt - Senior Research Analyst on HealthcareSean McGowan - Managing Director and Senior Research AnalystSusan Anderson - Managing Director and Senior AnalystOperatorI will no ...

BioHarvest Sciences (NasdaqGM:BHST) Q4 2025 Earnings call March 31, 2026 04:30 PM ET Speaker5I will now hand the call over to Justin Meacham, Head of Investor Relations. Please go ahead.Speaker3Greetings. With us on the call are Dr. Zaki Rakib, Chairman, Ilan Sobel, Chief Executive Officer, and Bar Dichter, Chief Financial Officer. Before we begin, I'd like to remind you that management will be making projections and forward-looking statements on the call today regarding future events. Any statements that a ...

HOUSTON, March 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced that it has granted inducement awards to two new employees who recently joined the Company. The awards were granted on March 26, 2026 under the Company’s 2015 New Employee Incentive Plan, as amended, which provides for the granting of equity awards to new ...